市場調查報告書
商品編碼
1394593
全球前列腺癌市場評估:按類型、癌症階段、方式、最終用戶、地區、機會、預測(2016-2030)Prostate Cancer Market Assessment, By Types, By Stages of Cancer, By Modality, By End-user, By Region, Opportunities and Forecast, 2016-2030F |
全球前列腺癌市場規模預計將從 2022 年的 117.1 億美元增至 2030 年的 218.4 億美元,在 2023-2030 年預測期內複合年增長率為 8.1%。 多種因素作用於市場,影響其流行、診斷、治療和研究。 市場的主要驅動因素是人口老化、全球前列腺癌負擔的增加、診斷工具的進步、早期檢測和篩檢、基因研究、意識和教育、治療創新、醫療保健和流行病學。趨勢、監管環境、不斷上升的趨勢醫療保健成本以及遠距醫療和數位醫療技術的採用。
影響市場的最突出因素之一是人口老化。 前列腺癌與年齡密切相關,因此隨著世界人口老化,前列腺癌的發生率將顯著增加。 診斷工具的進步也在推動市場方面發揮著至關重要的作用。 MRI 和 PET 掃描等診斷影像技術的創新正在提高前列腺癌的診斷準確性,從而實現更早、更準確的識別。 早期檢測和篩檢計劃,特別是廣泛使用的PSA(前列腺特異性抗原)檢測,有助於早期發現前列腺癌。 基因研究徹底改變了我們對前列腺癌的理解,並闡明了其潛在的分子和遺傳機制。 這些知識為標靶治療和精準醫學方法鋪平了道路,這些方法可以根據每個患者獨特的基因組成量身定制治療策略。
意識和教育活動提高了人們對定期檢查和篩檢重要性的認識。 製藥業的治療創新引入了新的藥物和治療方法,包括標靶療法和免疫療法。 這些創新透過提供更有效的治療選擇並刺激研發投資,正在推動全球前列腺癌市場的發展。 醫療保健的取得、流行病學趨勢、監管環境和不斷上漲的醫療保健成本相互作用,共同塑造了全球前列腺癌市場格局。 獲得健康服務的差異以及當地和全球經濟/社會因素影響前列腺癌的診斷和治療。 此外,遠距醫療和數位醫療技術的採用正在擴大醫療服務範圍,並促進前列腺癌患者的遠距會診和監測。 這種演變在服務不足的地區以及在健康危機期間親自訪問受到限制的情況下尤其重要。
世界各國政府正在透過多方面的方法積極應對前列腺癌發病率上升的問題,包括提高認識計劃和財政支持。 這些措施在加強全球前列腺癌市場方面發揮著至關重要的作用。 這項宣傳活動不僅教育大眾有關早期發現的風險和重要性,還減少了對該疾病的恥辱,並鼓勵更多的男性接受篩檢。 政府財政援助支持研究、醫療基礎設施和患者獲得治療。 這種綜合方法有助於全球前列腺癌市場的整體擴張。 例如,2023 年 9 月,加拿大政府宣布進行一項針對各種健康議題(包括攝護腺癌)的宣傳活動。 政府每年向加拿大抗癌夥伴關係 (CPAC) 撥款 5,000 萬美元,積極應對高癌症發病率問題。 借助這筆資金,CPAC 與加拿大癌症協會合作,將於 2023 年 7 月推出加拿大首個癌症特定數據計劃,即泛加拿大癌症數據戰略。 該策略旨在指導改善癌症相關數據的收集、整合和使用,最終改善癌症結果並提高加拿大各地的癌症護理質量,目的是提高公平性。
本報告研究和分析了全球前列腺癌市場,提供市場規模和預測、市場動態以及主要參與者的現狀和前景。
Global Prostate Cancer Market size was valued at USD 11.71 billion in 2022, which is expected to reach USD 21.84 billion in 2030 with a CAGR of 8.1% for the forecast period between 2023 and 2030F. Various elements affect the global prostate cancer market, influencing its prevalence, diagnosis, treatment, and research. Among the significant factors driving the global prostate cancer market are the aging population, increasing global burden of prostate cancer, advancements in diagnostic tools, early detection and screening, genetic research, awareness and education, therapeutic innovation, access to healthcare, epidemiological trends, the regulatory environment, rising healthcare expenditure, and the adoption of telemedicine and digital health technologies.
One of the most prominent factors impacting the global prostate cancer market is the aging population. As the world's population continues to grow older, the incidence of prostate cancer rises significantly since this disease is closely correlated with age. Advancements in diagnostic tools have also played a pivotal role in driving the global prostate cancer market. Innovations in imaging techniques like MRI and PET scans have enhanced the precision of prostate cancer diagnosis, leading to earlier and more accurate identification of the disease. Early detection and screening programs, particularly the widely used PSA (prostate-specific antigen) test, have been instrumental in identifying prostate cancer in its early stages. Genetic research has revolutionized the understanding of prostate cancer, elucidating its underlying molecular and genetic mechanisms. This knowledge has paved the way for targeted therapies and precision medicine approaches, tailoring treatment strategies to the specific genetic makeup of individual patients.
Awareness and education campaigns have heightened public consciousness about the importance of regular check-ups and screenings. Therapeutic innovation within the pharmaceutical industry has introduced novel drugs and treatment modalities, including targeted therapies and immunotherapies. These innovations provide more effective treatment options and stimulate investment in research and development, propelling the global prostate cancer market forward. Access to healthcare, epidemiological trends, regulatory environments, and rising healthcare expenditure all interact to shape the landscape of the global prostate cancer market. Disparities in access to healthcare services, coupled with regional and global economic and social factors, impact the diagnosis and treatment of prostate cancer. Furthermore, adopting telemedicine and digital health technologies has expanded the reach of healthcare services, facilitating remote consultations and monitoring for prostate cancer patients. This evolution is particularly vital in underserved areas or during times of health crises when in-person visits may be limited.
Prostate cancer is a widespread concern, affecting millions of men worldwide. It stands as the second most prevalent cancer in men, trailing only behind lung cancer, and contributes to 14.1% of all newly diagnosed cancer cases among men on a global scale, boosting the global prostate cancer market. Remarkably, in 112 countries, it ranks as the most frequently identified cancer in the male population. The year 2020 saw an estimated 1.41 million new cases of prostate cancer reported, with a sobering 375,304 deaths attributed to the disease across the globe. These distressing statistics place prostate cancer among the foremost causes of cancer-related mortality in men. Age plays a substantial role in the risk associated with prostate cancer, with over 85% of newly diagnosed patients being older than 60 years. Furthermore, a wide array of factors, including modifiable behaviors, prostate-specific antigen (PSA) screeni ng, metabolic attributes, and environmental influences, have been suggested as contributors to the varying epidemiological impact of the disease. Notably, the incidence and mortality rates of prostate cancer exhibit disparities according to ethnicity and geographical location. Developed countries such as North America, Western and Northern Europe, and Australia show higher prevalence rates compared to their developing counterparts, likely due to factors like a higher human development index (HDI), greater gross domestic product, and, subsequently, extended life expectancy.
Heightened awareness programs significantly influence the growth of the global prostate cancer market. These initiatives have played a vital role in educating individuals about the risks, symptoms, and the importance of regular screenings for prostate cancer. As a result, more men proactively seek early detection and treatment, thus increasing the demand for diagnostic and therapeutic services. Greater awareness fosters early intervention, improving outcomes and a higher survival rate. Consequently, the global prostate cancer market expands as a direct consequence of these educational efforts. For example, in December 2022, AstraZeneca unveiled "Never Miss," a global prostate cancer awareness campaign developed in collaboration with Merck & Co., rolled out in the United States and Canada. This initiative leverages the widespread enthusiasm for sports to motivate individuals to comprehend their susceptibility to prostate cancer. It also encourages those at risk to converse with their healthcare professionals.
Governments worldwide are actively addressing the rising incidence of prostate cancer through multifaceted approaches, including awareness programs and financial support. These efforts play a pivotal role in bolstering the global prostate cancer market. Awareness campaigns not only educate the public about the risks and importance of early detection but also reduce the stigma surrounding the disease, encouraging more men to seek screenings. Government financial aids support research, healthcare infrastructure, and patient access to treatments. This combined approach contributes to the overall expansion of the global prostate cancer market. As an example, in September 2023, the Canadian government unveiled awareness campaigns targeting various health issues, including prostate cancer. The government is actively addressing high cancer incidence rates by allocating an annual budget of $50 million to the Canadian Partnership Against Cancer (CPAC). With this financia l support, CPAC, in collaboration with the Canadian Cancer Society, introduced Canada's inaugural cancer-specific data initiative, known as The Pan-Canadian Cancer Data Strategy, in July 2023. This strategy is designed to guide efforts in improving the collection, integration, and utilization of cancer-related data, ultimately aiming to enhance cancer outcomes and elevate the quality and equity of cancer care throughout Canada.
Chemotherapy is a widely sought-after treatment for prostate cancer, and its prominence contributes significantly to the expansion of the global prostate cancer market. Chemotherapy involves the use of powerful drugs to target and kill cancer cells, making it a crucial option, especially for advanced or aggressive prostate cancer cases. As the incidence of prostate cancer continues to rise globally, the demand for effective treatment options, including chemotherapy, remains high. This growing demand propels the development of new chemotherapy drugs and therapies, fostering innovation and investment in the market. Moreover, it plays a pivotal role in improving the overall outlook for prostate cancer patients. As an example, in August 2023, Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, disclosed that the U.S. Food & Drug Administration (FDA) granted approval for AKEEGA (niraparib and abiraterone acetate). This marks the first-ever dual-action tablet to combine a PARP inhibitor with abiraterone acetate, administered alongside prednisone. The approval is specifically for the treatment of adult patients who have either confirmed deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) or suspected deleterious BRCA mutations as identified by an FDA-sanctioned test.
The global prostate cancer market is witnessing a growing demand for screening tests due to several key factors. Firstly, heightened awareness campaigns and educational efforts have encouraged men to be proactive about their health, increasing their willingness to undergo screening. Secondly, the aging population, which is more susceptible to prostate cancer, contributes to a higher demand for these tests. Additionally, advancements in diagnostic technologies have made screenings more accurate and accessible. This surge in demand for screening tests facilitates early detection and drives the growth of the prostate cancer market by necessitating further diagnostic and treatment services. As an example, LynxDx, a diagnostic solutions developer, introduced a novel non-invasive urine test for prostate cancer screening called MyProstateScore 2.0 (MPS2) in February 2023. This data-driven test is specifically tailored to deliver precise and categorized risk assessment information, aiding healthcare professionals in making clinical decisions for individuals with elevated prostate-specific antigen (PSA) levels or abnormal findings in digital rectal exams (DRE).
The future of the global prostate cancer market holds tremendous promise. Several factors contribute to this optimistic outlook. First and foremost, the aging population is on the rise, and prostate cancer is closely linked to age, ensuring a consistent demand for diagnosis and treatment. Advances in diagnostic tools, such as imaging technologies and genetic research, have improved early detection and personalized treatment strategies. The pharmaceutical industry continues to innovate with the introduction of targeted therapies and immunotherapies, offering more effective and precise treatment options. Awareness campaigns and proactive screening efforts have increased public consciousness about the importance of regular check-ups, leading to early diagnosis and intervention. Additionally, the adoption of telemedicine and digital health technologies has expanded healthcare access, particularly in underserved areas or during crises. These factors collectively create a bright future for the global prostate cancer market, ensuring better patient outcomes and continued growth.
In the global prostate cancer market, prominent companies are increasingly forging collaborative partnerships to advance the development of innovative and more efficacious pharmaceutical treatments. This strategic trend reflects the industry's recognition of the complex challenges posed by prostate cancer, encouraging joint research efforts and shared expertise. These collaborations aim to expedite the discovery and approval of novel drugs, which can offer improved therapeutic outcomes for patients, reduce side effects, and improve overall treatment effectiveness. By pooling resources and knowledge, these partnerships hold the potential to drive significant advancements in prostate cancer therapy, benefiting both patients and the healthcare industry. For example, in June 2023, the US Food and Drug Administration (FDA) authorized the use of a combination treatm ent involving AstraZeneca and MSD's Lynparza (Olaparib) along with conventional therapies for the management of metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations (BRCAm). This approval pertains to the utilization of Lynparza alongside the standard medications Zytiga and prednisone for mCRPC.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.